Shares of Arcturus Therapeutics Holdings climbed after posting a second-quarter loss and revenue that beat analyst expectations. Shares surged 29% to $13.69 Tuesday. The stock is down 13% this year.

A potential breakthrough in the ongoing AIDS crisis could be deprioritized due to the decisions of noted vaccine skeptic Robert F. Kennedy, Jr.

The "off-the-shelf" vaccine has also shown promising results for pancreatic cancer. Since the U.S. Preventive Services Task Force (USPSTF) changed its recommendation for when Americans at average risk ...

The U.S. Food and Drug Administration (FDA) is reportedly considering revoking the authorization granted to Pfizer Inc. (PFE) to sell its COVID-19 vaccine to children under five. According to a ...